HCPCS Code B4187: Omegaven, 10 grams lipids billing guide

Key Takeaways

HCPCS Code B4187 describes Omegaven (fish oil triglycerides) at 10 grams lipids, a parenteral nutrition lipid emulsion assigned by CMS effective January 2020

Coverage requires permanent gastrointestinal dysfunction under Medicare Part B’s prosthetic device benefit, billed through the DME MAC

Claims must include a physician order, ICD-10-CM diagnosis codes, and the KX modifier attesting that LCD coverage criteria are met — CMS eliminated CMN/DIF forms for dates of service on or after January 1, 2023

Practice management software like Pabau helps infusion practices keep structured clinical documentation and audit-ready records that support accurate B4187 coding

HCPCS Code B4187 is the billing code for Omegaven, 10 grams lipids — a fish oil-based IV lipid emulsion used in parenteral nutrition when a patient can’t tolerate standard soy-based lipids. It carries its own billing rules, coverage criteria, and documentation checklist, and getting any one of them wrong delays reimbursement.

This guide covers the official code descriptor, Medicare Part B coverage criteria, documentation requirements, billing units, ICD-10-CM companion codes, Medicare reimbursement, and adjacent B-series codes for billers, coders, and practice teams.

HCPCS Code B4187: Definition and official descriptor

HCPCS Code B4187 is a Level II HCPCS code assigned to Omegaven at 10 grams lipids. The official CMS descriptor reads: Omegaven, 10 grams lipids. The code belongs to the B-series of HCPCS Level II codes, which covers enteral and parenteral therapy supplies and nutritional products.

According to CMS, the agency permanently assigned B4187 effective January 2020, following FDA approval of Omegaven for use in pediatric patients with parenteral nutrition-associated cholestasis.

Omegaven is manufactured by Fresenius Kabi and consists of omega-3 fatty acid triglycerides derived from fish oil. It is used as a lipid emulsion component of parenteral nutrition therapy, particularly in patients who cannot tolerate or have developed complications from standard soy-based lipid emulsions.

The billing unit is per 10 grams of lipids administered, so a single infusion providing 20 grams of lipids would be billed as two units of B4187.

Code details at a glance

The table below summarizes the key code attributes billers need when setting up B4187 in their system or verifying a claim.

What does B4187 cover? Clinical overview of Omegaven

Omegaven is a 10% fish oil-based IV lipid emulsion used as a component of parenteral nutrition for patients who cannot receive adequate nutrition through the gastrointestinal tract. Unlike conventional soy-based lipid emulsions, which contain predominantly omega-6 fatty acids, Omegaven provides omega-3 fatty acids, particularly EPA and DHA, from fish oil triglycerides.

This composition makes it the preferred option for patients who develop parenteral nutrition-associated liver disease (PNALD) or parenteral nutrition-associated cholestasis (PNAC) when using standard lipid emulsions. Teams working in IV therapy EMR workflows will recognize these as high-documentation, high-complexity cases.

The patient populations most commonly receiving Omegaven under HCPCS Code B4187 include:

• Pediatric patients with parenteral nutrition-associated cholestasis (the primary FDA-approved indication)
• Patients with short-bowel syndrome who cannot tolerate soy-based lipid emulsions
• Adults with severe inflammatory conditions requiring parenteral lipid support
• Patients with intestinal failure requiring long-term home parenteral nutrition
• Patients who have developed elevated liver enzymes attributable to conventional lipid emulsions

Because Omegaven is a specialty product with a defined FDA-approved indication, payers scrutinize B4187 claims closely. Documentation of the clinical rationale for choosing Omegaven over a standard lipid emulsion is not optional. Payers expect it on every claim. Practices coordinating broader nutrition assessments for patients transitioning between parenteral and oral feeding may also find an elimination diet plan template useful for standardizing related documentation.

Medicare coverage criteria for HCPCS Code B4187

Medicare Part B covers parenteral nutrition products, including those billed under HCPCS Code B4187, as a prosthetic device benefit. Coverage is not automatic. Several clinical criteria must all be met before a claim is payable. Understanding state-level IV therapy compliance requirements is a separate layer, but Medicare’s federal criteria are the starting point for any B4187 claim.

CMS and DME MAC guidance establish the following coverage requirements:

• Permanent gastrointestinal dysfunction: The patient must have a documented permanent or long-duration severe impairment of the digestive system that prevents adequate nutritional absorption through the GI tract. Temporary conditions generally do not qualify.
• Medical necessity: The treating physician must certify that parenteral nutrition is the only clinically appropriate means of providing adequate nutrition for the patient.
• Home parenteral nutrition setting: Under Medicare Part B, B4187 is primarily covered in the home setting. Hospital-based PN is covered under Part A. The patient must be receiving care at home or in a covered facility.
• Omegaven-specific indication: For B4187 specifically, claims must reflect a clinical reason for using a fish oil-based emulsion rather than a standard soy-based product. Payers look for documentation of PNALD, PNAC, or intolerance to conventional lipids.
• Physician order: A signed, current physician order specifying the PN formula including Omegaven must be on file.

Coverage determinations also vary by MAC jurisdiction. Always consult the Local Coverage Determination (LCD) from your patient’s specific Durable Medical Equipment Medicare Administrative Contractor (DME MAC) before submitting B4187 claims.

Documentation requirements for B4187 claims

Claims that lack proper documentation are the primary driver of B4187 denials. Using digital clinical documentation forms structured around payer requirements significantly reduces this risk. Practices coordinating feeding and swallowing support alongside PN can standardize related documentation with a dysphagia care plan template. The following documents must be present and retrievable for every B4187 claim submitted to the DME MAC.

• Medical necessity documentation: CMS eliminated the CMN and DIF forms, including the parenteral/enteral nutrition CMS-10126, for dates of service on or after January 1, 2023 (CMS Transmittal SE22002). Medical necessity is now established through the medical record and the claim itself. Suppliers append the KX modifier to attest that all coverage criteria in the Parenteral Nutrition LCD (L38953) and its Policy Article (A58836) are met, and must retain the supporting evidence in their files for the DME MAC to review on request.
• Physician order: Signed order specifying the PN formulation, including the Omegaven component, concentration, infusion rate, and frequency.
• Diagnosis codes: ICD-10-CM codes documenting the GI dysfunction and, where applicable, the hepatic complication driving the selection of Omegaven over standard lipids.
• Treatment plan: A nutritional assessment and plan prepared by or in consultation with a registered dietitian, documenting caloric and macronutrient requirements.
• Progress notes: Ongoing clinical documentation confirming continued medical necessity, patient response to therapy, and any changes to the PN formula.
• Laboratory data: Liver function tests, nutritional markers (pre-albumin, albumin), and lipid profiles that support the switch to or continued use of Omegaven.

Maintaining HIPAA-compliant clinical records is a baseline requirement for all of this documentation. Practices must retain records and make them available for audit for a minimum of seven years in most MAC jurisdictions.

Practices managing IV therapy and infusion services should also review IV therapy intake documentation standards to ensure their intake processes capture the clinical detail payers require at the point of ordering. Following sound IV therapy best practices from the outset saves substantial rework at audit.

How to bill HCPCS Code B4187: Billing guidelines and units

B4187 is billed per 10 grams of lipids administered, not per infusion session or per vial. Billers handling mobile IV therapy billing must account for the exact volume of Omegaven dispensed rather than a flat per-visit unit. The billing calculation follows this logic:

1. Determine the total grams of lipids in the Omegaven infusion prescribed (e.g. 50 grams)
2. Divide by 10 to get the number of billable units (50 grams / 10 = 5 units of B4187)
3. Submit 5 units of B4187 on the claim for that infusion

Additional billing rules to observe:

• Submit to the DME MAC: B4187 is a DMEPOS code billed to the Durable Medical Equipment MAC, not the A/B MAC that handles most Part B physician services. Submitting to the wrong MAC is a common and correctable error.
• Place of service: Claims should reflect the patient’s home or covered care setting. Hospital-based PN does not use B4187 under Part B.
• Modifier usage: Append the KX modifier to attest that all coverage criteria in the Parenteral Nutrition LCD are met. This is the required attestation modifier on PEN claim lines, including B4187, now that CMN/DIF forms have been eliminated for current dates of service. RR (rental) applies to separately billed durable equipment, such as an infusion pump or IV pole, not to the nutrient solution code itself.
• Frequency limits: Payers may apply utilization edits. Document the prescribed frequency clearly and ensure the billed quantity matches the physician-ordered infusion schedule.
• Supplier enrollment: The supplier billing B4187 must be enrolled as a DMEPOS supplier and must have an active supplier agreement with CMS.

Use the AAPC’s HCPCS Level II code lookup or the PGM Billing HCPCS lookup tool to verify the current code status and descriptor before submitting any claim.

Cut denials on complex infusion codes

Pabau's structured clinical documentation tools help infusion and IV therapy practices capture complete, audit-ready records that support accurate B4187 coding. See how it works in a live demo.

Book a demo

ICD-10-CM codes commonly used with HCPCS Code B4187

Every B4187 claim must be supported by ICD-10-CM diagnosis codes that establish the medical necessity for parenteral nutrition and, where relevant, for Omegaven specifically. The codes below are the most commonly paired diagnoses. Verify current-year validity via the CDC/NCHS ICD-10-CM web tool, as CMS updates codes annually on October 1.

Staff responsible for coding should also understand who administers IV therapy to ensure the ordering provider’s credentials are documented alongside the diagnosis codes.

Use the most specific diagnosis code available. Unspecified codes are acceptable only when clinical documentation does not support a more specific code. Pairing the GI dysfunction diagnosis (e.g. K91.2) with the hepatic complication diagnosis (e.g. K76.89) strengthens the medical necessity argument for Omegaven specifically rather than a standard lipid emulsion.

Medicare reimbursement rate for B4187

Medicare reimbursement for HCPCS Code B4187 is determined by the CMS DMEPOS fee schedule, which is updated annually. CMS expresses rates per 10 grams of lipids, one billing unit, and they vary depending on whether the supplier is a participating or non-participating Medicare provider.

The CMS DMEPOS fee schedule provides the most current allowable amounts and should be consulted for each plan year rather than relying on prior-year figures.

Key points about B4187 reimbursement:

• Medicare sets rates at the lower of the supplier’s charge or the Medicare allowable amount
• Geographic adjustments run through the DMEPOS fee schedule’s regional single payment amounts, bounded by national floor and ceiling limits, with separate blended-rate rules (the CARES Act’s 50/50 and 75/25 blends) for rural and non-contiguous areas
• Medicaid reimbursement rates differ by state. New York Medicaid, for example, added B4187 to its parenteral nutrition coverage as of December 2023 per emedny provider communications
• Commercial payer rates are negotiated separately and may differ significantly from Medicare allowable amounts
• Always verify the current fee schedule with the Medicare Informatics HCPCS tables before providing cost estimates to patients or facilities

Related HCPCS codes for parenteral nutrition lipids

B4187 sits within a cluster of B-series codes covering parenteral nutrition components. Selecting the wrong adjacent code is a common source of claim errors. The table below compares the lipid, carbohydrate, and protein code families to help coders choose correctly. Codes like B4160 follow similar per-unit billing logic on the enteral side of parenteral and enteral nutrition (PEN) billing. Patients with intestinal failure or short-bowel syndrome, common indications for B4187, often also need separately billed ostomy supplies, such as A4367.

A single PN infusion typically generates claims across multiple B-series codes, and the mix depends on whether the base solution is homemix or premix. A homemix formulation bills the amino acid tier (B4168–B4178), the dextrose tier (B4164 or B4180), and the lipid component (B4187) as separate lines.

A premix formulation instead uses one banded code, such as B4189, to cover the combined amino acid and carbohydrate content, so those two components are not billed separately. Either way, B4187 remains its own line, since lipids are always billed independently of the amino acid/carbohydrate base.

How Pabau supports parenteral nutrition billing workflows

Infusion and home health practices billing HCPCS Code B4187 face a heavy documentation burden. A single claim needs a signed physician order, diagnosis coding, a nutritional assessment, progress notes, lab data, and a KX modifier attestation that LCD criteria are met, all coordinated across the physician, dietitian, and DME supplier. Missing any one of these creates a denial.

Pabau’s clinical documentation tools support this workflow with structured note templates, HCPCS code fields, and an audit trail, so the record a DME MAC needs to review is already in place before a claim goes out.

Practices using Pabau for infusion therapy can also leverage prescription management workflows to link physician orders directly to treatment records, ensuring the ordering clinician’s signed order is always attached to the relevant claim.

For teams managing IV therapy EMR software, the ability to attach lab results, infusion logs, and nutritional assessments within the patient record means the documentation package for a B4187 claim is assembled during care delivery rather than reconstructed during an audit.

Key capabilities relevant to B4187 billing workflows:

• Structured clinical note templates capturing infusion volume, lipid grams administered, and patient response
• HCPCS code entry with unit-quantity fields for per-10-gram billing calculations
• Digital storage for consent forms and supporting medical-necessity documentation, linked to the claim
• Automated recall prompts for progress note scheduling and periodic reassessment
• Audit log of all documentation changes for compliance review

Continue your research

Wondering what GI diagnoses often accompany parenteral nutrition claims? ICD-10 code K67 covers peritoneal disorders that can complicate GI dysfunction and often appear alongside B4187 claims.

Looking for compliant intake documentation for infusion patients? IV therapy intake templates provide structured intake documentation aligned with payer requirements for IV and infusion services.

Want to see how Pabau keeps clinical documentation audit-ready? Electronic medical records software shows how Pabau structures clinical notes, HCPCS code fields, and audit trails for complex billing scenarios.

Conclusion

Billing errors on B4187 claims almost always trace back to the same root causes: incomplete documentation, incorrect billing units, wrong MAC submission, or missing diagnosis code specificity. None of these are inevitable. A structured approach to PN documentation, from the physician order through to progress notes and lab data, eliminates most denials before they happen.

Pabau’s metabolic health EMR tools give infusion practices structured templates and audit-ready documentation to capture everything a DME MAC needs to review for a compliant B4187 claim. To see how it handles complex HCPCS documentation in practice, book a demo with the Pabau team.

Frequently asked questions